Search This Blog

Monday, March 6, 2023

Voyager: $25 M Payment for License of Next-Gen AAV Capsids for Multiple Neurologic Disease

 Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties

With option exercise, potential to expand agreement to include capsids for up to two additional targets extends for next 18 months

https://finance.yahoo.com/news/voyager-therapeutics-receive-25-million-120000507.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.